Copyright: © 2025 The Author(s). Published by Elsevier Inc. on behalf of Society for Mucosal Immunology.
Karen Hoffmann, Ulrike Behrendt, Peter Pennitz, Holger Kirsten, Jessica Pohl, Elena Lopez-Rodriguez, Chantal Weissfuss, Jens Kollmeier, Mario Tönnies, Sebastian Brill, Konrad Steinestel, Martin Witzenrath, Werner Wenzel, Christian Zobel, and Geraldine Nouailles. J Clin Invest. 2025 (In-Press Preview)
To access the full article, click here:
Pseudomonas aeruginosa ventilator-associated pneumonia (VAP) is one of the most frequent nosocomial infections in mechanically ventilated ICU patients, with mortality rates ranging from 24 to 76%, worsened by multi-drug resistance. Still, VAP pathophysiology remains unclear, partly due to limited model systems. Today, organotypic models, like the Emulate® alveolus chip, can replicate alveolar-capillary physiology, including air-liquid interface (ALI), vascular flow, and mechanical forces. Here, we advanced the alveolus-chip into a Pseudomonas pneumonia-on-a-chip (POC) model using human primary pulmonary microvascular endothelial cells (HPMVECs) and human alveolar epithelial cells of different origin.
